Nevada Cancer Institute

Phase	Trial	Trial Status	Site Status	Drug	NCT#
1	A Phase IA, two-arm, multi-center, dose escalating study of LBH589 administered intravenously on two dose schedules in adult patients with advanced solid tumors & non-Hodgkin’s lymphoma.	Ongoing, but not recruiting	Closed	LBH589	NVCI
1	Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients.	Ongoing, but not recruiting	Closed	AUY922	NCT00526045
1	A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer	Ongoing, but not recruiting	Closed	BEZ235	NCT00620594
1	A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer	Completed	Closed	BGT226	NCT00600275